Loading
A phase 2 trial of Zolbetuximab, Oxaliplatin, Pembrolizumab, Leucovorin (folinic acid), Nivolumab and Docetaxel in gastric & gastro-oesophageal junction cancer, run by Astellas Pharma Global Development, Inc., active and no longer recruiting.
A Study of Zolbetuximab (IMAB362) in Adults With Gastric Cancer is a phase 2 interventional study registered as NCT03505320 by Astellas Pharma Global Development, Inc., with 143 participants enrolled, started 2018-06-29 and due to reach its primary completion in 2027-06-30. Interventions recorded: zolbetuximab, oxaliplatin, leucovorin, fluorouracil, Pembrolizumab and folinic acid.
Shares Zolbetuximab, Astellas, Leucovorin (folinic acid), Oxaliplatin and the tag pipeline.
Shares Zolbetuximab, Astellas, Monoclonal antibodies and the tag pipeline.
Shares Astellas, Oxaliplatin, Pembrolizumab and the tag pipeline.
Shares Zolbetuximab, Oxaliplatin, Nivolumab, Gastric & gastro-oesophageal junction cancer and the tag pipeline.
Shares Oxaliplatin, Nivolumab, Gastric & gastro-oesophageal junction cancer and the tag pipeline.
Shares Leucovorin (folinic acid), Oxaliplatin, Monoclonal antibodies and the tag pipeline.
Shares Oxaliplatin, Monoclonal antibodies, Gastric & gastro-oesophageal junction cancer, Pembrolizumab and the tag pipeline.
Shares Oxaliplatin, Monoclonal antibodies, Gastric & gastro-oesophageal junction cancer and the tag pipeline.